Cargando…

Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis

INTRODUCTION: The aim of this study was to evaluate guselkumab efficacy on regional psoriasis in a subset of psoriasis patients with a self-reported psoriatic arthritis (PsA) diagnosis. METHODS: In the phase 3 VOYAGE-1 and -2 studies, at week (W)0, patients with moderate-to-severe psoriasis were ran...

Descripción completa

Detalles Bibliográficos
Autores principales:	Orbai, Ana-Maria, Chakravarty, Soumya D., You, Yin, Shawi, May, Yang, Ya-Wen, Merola, Joseph F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613182/ https://www.ncbi.nlm.nih.gov/pubmed/37713133 http://dx.doi.org/10.1007/s13555-023-01012-z

Ejemplares similares

Underdiagnosed and undertreated psoriasis: Nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails
por: Merola, Joseph F., et al.
Publicado: (2018)

Clinical Characteristics of Registry Participants with Psoriatic Arthritis Initiating Guselkumab: An Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2022)

A case of severe psoriatic arthritis with hands flexion contracture and palmar psoriasis successfully treated with guselkumab
por: Megna, Matteo, et al.
Publicado: (2022)

Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study
por: Schett, Georg, et al.
Publicado: (2023)

A Novel Qualitative Study Assessing Patient-Reported Outcome Measures Among People Living with Psoriatic Arthritis or Ankylosing Spondylitis
por: Chakravarty, Soumya D., et al.
Publicado: (2021)

Correction: Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study
por: Schett, Georg, et al.
Publicado: (2023)

Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study
por: Mease, Philip J., et al.
Publicado: (2023)

Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2023)

A Case of Nail Psoriasis Improved by Treatment with Golimumab in a Psoriatic Arthritis Patient
por: Jung, So Young
Publicado: (2017)

Evaluation of Improvement in Skin and Nail Psoriasis in Bio‐naïve Patients With Active Psoriatic Arthritis Treated With Golimumab: Results Through Week 52 of the GO‐VIBRANT Study
por: Mease, Philip, et al.
Publicado: (2020)

Paradoxical psoriatic arthritis flare with the initiation of brodalumab and guselkumab
por: Kashlan, Reem, et al.
Publicado: (2021)

Guselkumab-induced vitiligo in a patient with psoriatic arthritis
por: Martora, Fabrizio, et al.
Publicado: (2023)

Ultrasound Assessment of Changes in Nails in Psoriasis and Psoriatic Arthritis
por: Krajewska-Włodarczyk, Magdalena, et al.
Publicado: (2018)

Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis
por: Mease, Philip J, et al.
Publicado: (2022)

Arthritis Interception in Patients with Psoriasis Treated with Guselkumab
por: Zabotti, Alen, et al.
Publicado: (2021)

Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis
por: Coates, Laura C, et al.
Publicado: (2022)

Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis
por: Mease, Philip J, et al.
Publicado: (2021)

Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies
por: Ritchlin, Christopher T, et al.
Publicado: (2022)

Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial
por: Gladman, Dafna D., et al.
Publicado: (2022)

The Frequency of Association of Nail Involvement and Psoriatic Arthritis in Psoriasis Patients
por: Pala, Erdal, et al.
Publicado: (2023)

Nail Ultrasound in Psoriasis and Psoriatic Arthritis—A Narrative Review
por: Agache, Mihaela, et al.
Publicado: (2023)

Guselkumab, a Selective Interleukin‐23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies
por: McGonagle, Dennis, et al.
Publicado: (2023)

Guselkumab for plaque psoriasis
Publicado: (2019)

Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies
por: McGonagle, Dennis, et al.
Publicado: (2021)

Guselkumab: widened action in psoriatic disease
por: Arnone, Marcelo, et al.
Publicado: (2021)

A Case of the Safety and Efficacy of Guselkumab in Psoriasis with Alcoholic Liver Cirrhosis
por: Nam, Hyun Min, et al.
Publicado: (2021)

Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis
por: Gottlieb, Alice B, et al.
Publicado: (2023)

Psoriatic Arthritis and Nail Psoriasis in a Patient with Concomitant Atopic Dermatitis
por: Eichhoff, Gerhard, et al.
Publicado: (2018)

A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
por: Kirkham, Bruce W., et al.
Publicado: (2023)

Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas’ Psoriasis Registry
por: Walsh, Jessica A., et al.
Publicado: (2021)

Population pharmacokinetics and exposure‐response modeling analyses of guselkumab in patients with psoriatic arthritis
por: Chen, Yang, et al.
Publicado: (2021)

Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
por: Elewski, Boni E., et al.
Publicado: (2022)

Nail involvement in psoriatic arthritis
por: Sobolewski, Piotr, et al.
Publicado: (2017)

Nails in Feet
por: Bell, John A.
Publicado: (1894)

Guselkumab for the treatment of psoriasis – evidence to date
por: Nogueira, Miguel, et al.
Publicado: (2019)

Coexistence of Fungal Infections in Psoriatic Nails and their Correlation with Severity of Nail Psoriasis
por: Chaowattanapanit, Suteeraporn, et al.
Publicado: (2018)

The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial
por: Ritchlin, Christopher T., et al.
Publicado: (2023)

Comparative microscopic analysis of nail clippings from patients with cutaneous psoriasis and psoriatic arthritis
por: Fonseca, Gabriela Poglia, et al.
Publicado: (2017)

The Combination of IL-6, PLR and Nail Psoriasis: Screen for the Early Diagnosis of Psoriatic Arthritis
por: Liu, Xiaoyang, et al.
Publicado: (2023)

Enlarged hands and feet – Not always acromegaly
por: Ghatnatti, Vikrant, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_bvikn7tb3b24rbekln2ke8pcgq